Hedgehog ligand biogenesis (Homo sapiens)

From WikiPathways

Jump to: navigation, search
6-10, 14, 17...74, 7, 11, 49, 52...1, 9, 19, 22, 39...31, 492, 3, 10, 29, 33...6, 15, 18, 24, 40...4, 7, 11, 30, 49...21, 28, 434, 7, 11, 30, 41...6, 40, 467, 497, 99, 4112, 13, 25, 26, 45...5, 7, 10, 16, 17, 20...7, 497, 494, 7, 4974, 7, 49cytosolendoplasmic reticulum lumenERLEC1 N4glycoAsn-DHH(199-396) VCP ERLEC1 ub SHH(24-462) C198S UBC(153-228) PSMC2 SHH processingvariants:OS9/ERLEC1PSMA1 ub SHH(24-462) W117G N4glycoAsn-DHH(199-396) HHATPSME4 VCP N4glycoAsn-2xHC-IHH(28-411) SRR SHH variants DERL2 GPI-GPC5 SRR SHH variants SHH(24-462) C198S UBC(77-152) SEL1L ub cholesterol site mutants of SHH NglycoAsn-Hhprecursors:P4HBSHH(24-462) C198S SYVN1(1-617) ub-SHHprocessingvariants:ERLEC:OS9:SEL1:SYVN1 dimer:DERL2:VCP hexamerub-N4glycoAsn-IHH(203-411) cholesterol site variants of SHH CHOL-N-palmitoyl-L-cysteine-IHH(28-202) SHH(34-?) 2xHC-DHH(23-396) N4glycoAsn-IHH(203-411) CHOL-N-palmitoyl-L-cysteine-DHH(23-198) CHOL-SHH(24-197) SCUBE2 UbPSME3 SHH(24-462) W117G ERLEC1 PSMD12 ub SRR SHH variants N4glycoAsn-DHH(199-396) PSMB2 DERL2 DHH(33-?) OS9 SYVN1(1-617) PSMF1 PSMA6 DERL2 ub-N4glycoAsn-IHH(203-411) PSMB1 UBC(609-684) PSMD6 CHOL-N-palmitoyl-L-cysteine-DHH(23-198) PSMD13 PSMA3 N4glycoAsn-2xHC-IHH(28-411) ERLEC1 DISP2UBB(153-228) OS9 CHOL-N-palmitoyl-L-cysteine-DHH(23-198) UBA52(1-76) PSMD11 IHH PSMB8 CHOL-N-palmitoyl-L-cysteine-IHH(28-202) H2OSYVN1(1-617) ERLEC1 CoA-SHUBC(1-76) ub-C-terminalHhfragments:ERLEC/OS9:SEL1:SYVN1dimer:DERL2:VCP hexamerN4glycoAsn-2xHC-DHH(23-396) OS9/ERLEC1OS9 ub-N4glycoAsn-DHH(199-396) SEL1:SYVN1dimer:DERL2:VCPhexamerSEL1L CHOL-N-palmitoyl-L-cysteine-DHH(23-198) CHOL-N-palmitoyl-L-cysteine-IHH(28-202) Hh-Np:GPC5SEL1L NglycoAsn-HhprecursorsPSME2 C-terminalHhfragments:ERLEC/OS9:SEL1:SYVN1dimer:DERL2:VCP hexamerDISP2 N4glycoAsn-IHH(203-411) PSMB3 PSME1 Hh-Npp2xHC-IHH(28-411) PSMD5 N4glycoAsn-2xHC-SHH(24-462) PSMA8 P4HB UBC(457-532) PSMC3 ERLEC1 SHHprocessingvariants:ERLEC:OS9:SEL1:SYVN1 dimer:DERL2:VCP hexamerH2OPSMD3 CHOL-N-palmitoyl-L-cysteine-SHH(24-197) Hh-NpPSMD14 26S proteasomeSRR SHH variants ub SHH(24-462) W117R ub-SHH(24-462) W117R GPI-cleaved GPC5 ub-SHH(24-462) W117G NOTUMPSMD10 PSMB6 CHOL-N-palmitoyl-L-cysteine-SHH(24-197) PSMB7 C-terminal HhfragmentsSHH(24-462) W117R PSMD1 Hh precursorsub C-terminal HhfragmentsPSMB9 ADPCHOL-N-palmitoyl-L-cysteine-DHH(23-198) PSMC5 ATPSEL1L CHOL-N-palmitoyl-L-cysteine-SHH(24-197) PSMC4 PSMD8 ub-SHH variantsVCP ub cholesterol site variants of SHH N4glycoAsn-SHH(198-462) ERLEC1 CHOL-N-palmitoyl-L-cysteine-SHH(24-197) N4glycoAsn-SHH(198-462) PSMB5 UBB(1-76) ub-N4glycoAsn-SHH(198-462) SYVN1(1-617) cholesterol site variants of SHH ADAM17CHOL-N-palmitoyl-L-cysteine-SHH(24-197) Palmitoyl-CoACHOL-N-palmitoyl-L-cysteine-DHH(23-198) PSMD2 SHH(24-462) W117G SHH(24-462) C198S RPS27A(1-76) phosphateN-terminal CHOL-HhfragmentsSHH variantsVCP PSMA7 ATPSHH(24-462) W117G DERL2 PSMC1 CHOL-N-palmitoyl-L-cysteine-IHH(28-202) PSMD4 P4HB2xHC-SHH(24-462) N4glycoAsn-IHH(203-411) PSMA4 OS9 UBC(229-304) PSMA2 CHOL-DHH(23-198) CHOL-N-palmitoyl-L-cysteine-SHH(24-197) CHOL-N-palmitoyl-L-cysteine-IHH(28-202) OS9 PSMD7 ADPUBC(381-456) C-terminalHhfragments:OS9/ERLEC1CHOLSEL1L OS9 Hh-Np:SCUBE2PSMD9 N4glycoAsn-SHH(198-462) ub-SHH(24-462) C198S ub SRR SHH mutants UBC(533-608) SYVN1(1-617) ub-N4glycoAsn-DHH(199-396) OS9 UBB(77-152) PSMB11 VCP Hh-NpHh-Np:DISP2SHH(24-462) W117R ub-N4glycoAsn-SHH(198-462) CHOL-N-palmitoyl-L-cysteine-IHH(28-202) N4glycoAsn-2xHC-SHH(24-462) N4glycoAsn-2xHC-DHH(23-396) Hh-Np:GPI-GPC5SHFM1 SHH(24-462) W117R SCUBE2DERL2 PSMB10 PSMC6 PSMA5 UBC(305-380) CHOL-IHH(28-202) cholesterol site variants of SHH GPI-GPC5PSMB4 32562332563232565632325623, 3432563232563231323232497, 49325656325622


Description

Mammalian genomes encode three Hedgehog ligands, Sonic Hedgehog (SHH), Indian Hedgehog (IHH) and Desert Hedgehog (DHH). These secreted morphogens can remain associated with lipid rafts on the surface of the secreting cell and affect developmental processes in adjacent cells. Alternatively, they can be released by proteolysis or packaging into vesicles or lipoprotein particles and dispersed to act on distant cells. SHH activity is required for organization of the limb bud, notochord and neural plate, IHH regulates bone and cartilage development and is partially redundant with SHH, and DHH contributes to germ cell development in the testis and formation of the peripheral nerve sheath (reviewed in Pan et al, 2013).

Despite divergent biological roles, all Hh ligands are subject to proteolytic processing and lipid modification during transit to the surface of the secreting cell (reviewed in Gallet, 2011). Precursor Hh undergoes autoproteolytic cleavage mediated by the C-terminal region to yield an amino-terminal peptide Hh-Np (also referred to as Hh-N) (Chen et al, 2011). No other well defined role for the C-terminal region of Hh has been identified, and the secreted Hh-Np is responsible for all Hh signaling activity. Hh-Np is modified with cholesterol and palmitic acid during transit through the secretory system, and both modifications contribute to the activity of the ligand (Porter et al, 1996; Pepinsky et al, 1998; Chamoun et al, 2001).

At the cell surface, Hh-Np remains associated with the secreting cell membrane by virtue of its lipid modifications, which promote clustering of Hh-Np into lipid rafts (Callejo et al, 2006; Peters et al, 2004). Long range dispersal of Hh-Np depends on the untethering of the ligand from the membrane through a variety of mechanisms. These include release of monomers through the combined activity of the transmembrane protein Dispatched (DISP2) and the secreted protein SCUBE2, assembly into soluble multimers or apolipoprotein particles or release on the surface of exovesicles (Vyas et al, 2008; Tukachinsky et al, 2012; Chen 2004; Zeng et al, 2001; reviewed in Briscoe and Therond, 2013). View original pathway at Reactome.

Comments

Reactome-Converter 
Pathway is converted from Reactome ID: 5358346
Reactome-version 
Reactome version: 75
Reactome Author 
Reactome Author: Rothfels, Karen

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Capurro MI, Shi W, Filmus J.; ''LRP1 mediates Hedgehog-induced endocytosis of the GPC3-Hedgehog complex.''; PubMed Europe PMC Scholia
  2. Buglino JA, Resh MD.; ''Hhat is a palmitoylacyltransferase with specificity for N-palmitoylation of Sonic Hedgehog.''; PubMed Europe PMC Scholia
  3. Buglino JA, Resh MD.; ''Identification of conserved regions and residues within Hedgehog acyltransferase critical for palmitoylation of Sonic Hedgehog.''; PubMed Europe PMC Scholia
  4. Vembar SS, Brodsky JL.; ''One step at a time: endoplasmic reticulum-associated degradation.''; PubMed Europe PMC Scholia
  5. Jiang J, Hui CC.; ''Hedgehog signaling in development and cancer.''; PubMed Europe PMC Scholia
  6. Tukachinsky H, Kuzmickas RP, Jao CY, Liu J, Salic A.; ''Dispatched and scube mediate the efficient secretion of the cholesterol-modified hedgehog ligand.''; PubMed Europe PMC Scholia
  7. Chen X, Tukachinsky H, Huang CH, Jao C, Chu YR, Tang HY, Mueller B, Schulman S, Rapoport TA, Salic A.; ''Processing and turnover of the Hedgehog protein in the endoplasmic reticulum.''; PubMed Europe PMC Scholia
  8. Pan A, Chang L, Nguyen A, James AW.; ''A review of hedgehog signaling in cranial bone development.''; PubMed Europe PMC Scholia
  9. Gallet A.; ''Hedgehog morphogen: from secretion to reception.''; PubMed Europe PMC Scholia
  10. Pepinsky RB, Zeng C, Wen D, Rayhorn P, Baker DP, Williams KP, Bixler SA, Ambrose CM, Garber EA, Miatkowski K, Taylor FR, Wang EA, Galdes A.; ''Identification of a palmitic acid-modified form of human Sonic hedgehog.''; PubMed Europe PMC Scholia
  11. Mueller B, Klemm EJ, Spooner E, Claessen JH, Ploegh HL.; ''SEL1L nucleates a protein complex required for dislocation of misfolded glycoproteins.''; PubMed Europe PMC Scholia
  12. Traister A, Shi W, Filmus J.; ''Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface.''; PubMed Europe PMC Scholia
  13. Eugster C, Panáková D, Mahmoud A, Eaton S.; ''Lipoprotein-heparan sulfate interactions in the Hh pathway.''; PubMed Europe PMC Scholia
  14. Vyas N, Goswami D, Manonmani A, Sharma P, Ranganath HA, VijayRaghavan K, Shashidhara LS, Sowdhamini R, Mayor S.; ''Nanoscale organization of hedgehog is essential for long-range signaling.''; PubMed Europe PMC Scholia
  15. Nakano Y, Kim HR, Kawakami A, Roy S, Schier AF, Ingham PW.; ''Inactivation of dispatched 1 by the chameleon mutation disrupts Hedgehog signalling in the zebrafish embryo.''; PubMed Europe PMC Scholia
  16. Porter JA, Ekker SC, Park WJ, von Kessler DP, Young KE, Chen CH, Ma Y, Woods AS, Cotter RJ, Koonin EV, Beachy PA.; ''Hedgehog patterning activity: role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain.''; PubMed Europe PMC Scholia
  17. Porter JA, Young KE, Beachy PA.; ''Cholesterol modification of hedgehog signaling proteins in animal development.''; PubMed Europe PMC Scholia
  18. Burke R, Nellen D, Bellotto M, Hafen E, Senti KA, Dickson BJ, Basler K.; ''Dispatched, a novel sterol-sensing domain protein dedicated to the release of cholesterol-modified hedgehog from signaling cells.''; PubMed Europe PMC Scholia
  19. Witt RM, Hecht ML, Pazyra-Murphy MF, Cohen SM, Noti C, van Kuppevelt TH, Fuller M, Chan JA, Hopwood JJ, Seeberger PH, Segal RA.; ''Heparan sulfate proteoglycans containing a glypican 5 core and 2-O-sulfo-iduronic acid function as Sonic Hedgehog co-receptors to promote proliferation.''; PubMed Europe PMC Scholia
  20. Huang X, Litingtung Y, Chiang C.; ''Region-specific requirement for cholesterol modification of sonic hedgehog in patterning the telencephalon and spinal cord.''; PubMed Europe PMC Scholia
  21. Dierker T, Dreier R, Petersen A, Bordych C, Grobe K.; ''Heparan sulfate-modulated, metalloprotease-mediated sonic hedgehog release from producing cells.''; PubMed Europe PMC Scholia
  22. Li F, Shi W, Capurro M, Filmus J.; ''Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling.''; PubMed Europe PMC Scholia
  23. Wei SJ, Williams JG, Dang H, Darden TA, Betz BL, Humble MM, Chang FM, Trempus CS, Johnson K, Cannon RE, Tennant RW.; ''Identification of a specific motif of the DSS1 protein required for proteasome interaction and p53 protein degradation.''; PubMed Europe PMC Scholia
  24. Ma Y, Erkner A, Gong R, Yao S, Taipale J, Basler K, Beachy PA.; ''Hedgehog-mediated patterning of the mammalian embryo requires transporter-like function of dispatched.''; PubMed Europe PMC Scholia
  25. Takeo S, Akiyama T, Firkus C, Aigaki T, Nakato H.; ''Expression of a secreted form of Dally, a Drosophila glypican, induces overgrowth phenotype by affecting action range of Hedgehog.''; PubMed Europe PMC Scholia
  26. Han C, Yan D, Belenkaya TY, Lin X.; ''Drosophila glypicans Dally and Dally-like shape the extracellular Wingless morphogen gradient in the wing disc.''; PubMed Europe PMC Scholia
  27. Peters C, Wolf A, Wagner M, Kuhlmann J, Waldmann H.; ''The cholesterol membrane anchor of the Hedgehog protein confers stable membrane association to lipid-modified proteins.''; PubMed Europe PMC Scholia
  28. Ohlig S, Farshi P, Pickhinke U, van den Boom J, Höing S, Jakuschev S, Hoffmann D, Dreier R, Schöler HR, Dierker T, Bordych C, Grobe K.; ''Sonic hedgehog shedding results in functional activation of the solubilized protein.''; PubMed Europe PMC Scholia
  29. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA.; ''Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.''; PubMed Europe PMC Scholia
  30. Hosokawa N, Kamiya Y, Kamiya D, Kato K, Nagata K.; ''Human OS-9, a lectin required for glycoprotein endoplasmic reticulum-associated degradation, recognizes mannose-trimmed N-glycans.''; PubMed Europe PMC Scholia
  31. Liu T, Qian WJ, Gritsenko MA, Camp DG, Monroe ME, Moore RJ, Smith RD.; ''Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.''; PubMed Europe PMC Scholia
  32. Roessler E, El-Jaick KB, Dubourg C, Vélez JI, Solomon BD, Pineda-Alvarez DE, Lacbawan F, Zhou N, Ouspenskaia M, Paulussen A, Smeets HJ, Hehr U, Bendavid C, Bale S, Odent S, David V, Muenke M.; ''The mutational spectrum of holoprosencephaly-associated changes within the SHH gene in humans predicts loss-of-function through either key structural alterations of the ligand or its altered synthesis.''; PubMed Europe PMC Scholia
  33. Chen MH, Li YJ, Kawakami T, Xu SM, Chuang PT.; ''Palmitoylation is required for the production of a soluble multimeric Hedgehog protein complex and long-range signaling in vertebrates.''; PubMed Europe PMC Scholia
  34. Voges D, Zwickl P, Baumeister W.; ''The 26S proteasome: a molecular machine designed for controlled proteolysis.''; PubMed Europe PMC Scholia
  35. Hardy RY, Resh MD.; ''Identification of N-terminal residues of Sonic Hedgehog important for palmitoylation by Hedgehog acyltransferase.''; PubMed Europe PMC Scholia
  36. Callejo A, Torroja C, Quijada L, Guerrero I.; ''Hedgehog lipid modifications are required for Hedgehog stabilization in the extracellular matrix.''; PubMed Europe PMC Scholia
  37. Zeng X, Goetz JA, Suber LM, Scott WJ, Schreiner CM, Robbins DJ.; ''A freely diffusible form of Sonic hedgehog mediates long-range signalling.''; PubMed Europe PMC Scholia
  38. Guerrero I, Chiang C.; ''A conserved mechanism of Hedgehog gradient formation by lipid modifications.''; PubMed Europe PMC Scholia
  39. Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J.; ''Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding.''; PubMed Europe PMC Scholia
  40. Creanga A, Glenn TD, Mann RK, Saunders AM, Talbot WS, Beachy PA.; ''Scube/You activity mediates release of dually lipid-modified Hedgehog signal in soluble form.''; PubMed Europe PMC Scholia
  41. Briscoe J, Thérond PP.; ''The mechanisms of Hedgehog signalling and its roles in development and disease.''; PubMed Europe PMC Scholia
  42. Li Y, Zhang H, Litingtung Y, Chiang C.; ''Cholesterol modification restricts the spread of Shh gradient in the limb bud.''; PubMed Europe PMC Scholia
  43. Ohlig S, Pickhinke U, Sirko S, Bandari S, Hoffmann D, Dreier R, Farshi P, Götz M, Grobe K.; ''An emerging role of Sonic hedgehog shedding as a modulator of heparan sulfate interactions.''; PubMed Europe PMC Scholia
  44. Porter JA, von Kessler DP, Ekker SC, Young KE, Lee JJ, Moses K, Beachy PA.; ''The product of hedgehog autoproteolytic cleavage active in local and long-range signalling.''; PubMed Europe PMC Scholia
  45. Ayers KL, Gallet A, Staccini-Lavenant L, Thérond PP.; ''The long-range activity of Hedgehog is regulated in the apical extracellular space by the glypican Dally and the hydrolase Notum.''; PubMed Europe PMC Scholia
  46. Johnson JL, Hall TE, Dyson JM, Sonntag C, Ayers K, Berger S, Gautier P, Mitchell C, Hollway GE, Currie PD.; ''Scube activity is necessary for Hedgehog signal transduction in vivo.''; PubMed Europe PMC Scholia
  47. Williamson D, Selfe J, Gordon T, Lu YJ, Pritchard-Jones K, Murai K, Jones P, Workman P, Shipley J.; ''Role for amplification and expression of glypican-5 in rhabdomyosarcoma.''; PubMed Europe PMC Scholia
  48. Traiffort E, Dubourg C, Faure H, Rognan D, Odent S, Durou MR, David V, Ruat M.; ''Functional characterization of sonic hedgehog mutations associated with holoprosencephaly.''; PubMed Europe PMC Scholia
  49. Huang CH, Hsiao HT, Chu YR, Ye Y, Chen X.; ''Derlin2 protein facilitates HRD1-mediated retro-translocation of sonic hedgehog at the endoplasmic reticulum.''; PubMed Europe PMC Scholia
  50. Lee JJ, Ekker SC, von Kessler DP, Porter JA, Sun BI, Beachy PA.; ''Autoproteolysis in hedgehog protein biogenesis.''; PubMed Europe PMC Scholia
  51. Callier P, Calvel P, Matevossian A, Makrythanasis P, Bernard P, Kurosaka H, Vannier A, Thauvin-Robinet C, Borel C, Mazaud-Guittot S, Rolland A, Desdoits-Lethimonier C, Guipponi M, Zimmermann C, Stévant I, Kuhne F, Conne B, Santoni F, Lambert S, Huet F, Mugneret F, Jaruzelska J, Faivre L, Wilhelm D, Jégou B, Trainor PA, Resh MD, Antonarakis SE, Nef S.; ''Loss of function mutation in the palmitoyl-transferase HHAT leads to syndromic 46,XY disorder of sex development by impeding Hedgehog protein palmitoylation and signaling.''; PubMed Europe PMC Scholia
  52. Hosokawa N, Wada I, Nagasawa K, Moriyama T, Okawa K, Nagata K.; ''Human XTP3-B forms an endoplasmic reticulum quality control scaffold with the HRD1-SEL1L ubiquitin ligase complex and BiP.''; PubMed Europe PMC Scholia
  53. Christianson JC, Shaler TA, Tyler RE, Kopito RR.; ''OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD.''; PubMed Europe PMC Scholia
  54. Giráldez AJ, Copley RR, Cohen SM.; ''HSPG modification by the secreted enzyme Notum shapes the Wingless morphogen gradient.''; PubMed Europe PMC Scholia
  55. Chamoun Z, Mann RK, Nellen D, von Kessler DP, Bellotto M, Beachy PA, Basler K.; ''Skinny hedgehog, an acyltransferase required for palmitoylation and activity of the hedgehog signal.''; PubMed Europe PMC Scholia
  56. Maity T, Fuse N, Beachy PA.; ''Molecular mechanisms of Sonic hedgehog mutant effects in holoprosencephaly.''; PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
114749view16:23, 25 January 2021ReactomeTeamReactome version 75
113193view11:26, 2 November 2020ReactomeTeamReactome version 74
112419view15:36, 9 October 2020ReactomeTeamReactome version 73
101323view11:21, 1 November 2018ReactomeTeamreactome version 66
100860view20:53, 31 October 2018ReactomeTeamreactome version 65
100401view19:27, 31 October 2018ReactomeTeamreactome version 64
99949view16:11, 31 October 2018ReactomeTeamreactome version 63
99505view14:44, 31 October 2018ReactomeTeamreactome version 62 (2nd attempt)
93767view13:34, 16 August 2017ReactomeTeamreactome version 61
93291view11:19, 9 August 2017ReactomeTeamreactome version 61
87463view14:10, 22 July 2016MkutmonOntology Term : 'Hedgehog signaling pathway' added !
86377view09:16, 11 July 2016ReactomeTeamreactome version 56
83415view11:10, 18 November 2015ReactomeTeamVersion54
81610view13:09, 21 August 2015ReactomeTeamNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
26S proteasomeComplexR-HSA-68819 (Reactome)
2xHC-DHH(23-396) ProteinO43323 (Uniprot-TrEMBL)
2xHC-IHH(28-411) ProteinQ14623 (Uniprot-TrEMBL)
2xHC-SHH(24-462) ProteinQ15465 (Uniprot-TrEMBL)
ADAM17ProteinP78536 (Uniprot-TrEMBL)
ADPMetaboliteCHEBI:456216 (ChEBI)
ATPMetaboliteCHEBI:30616 (ChEBI)
C-terminal

Hh

fragments:ERLEC/OS9:SEL1:SYVN1dimer:DERL2:VCP hexamer
ComplexR-HSA-5362413 (Reactome)
C-terminal

Hh

fragments:OS9/ERLEC1
ComplexR-HSA-5362409 (Reactome)
C-terminal Hh fragmentsComplexR-HSA-5358286 (Reactome)
CHOL-DHH(23-198) ProteinO43323 (Uniprot-TrEMBL)
CHOL-IHH(28-202) ProteinQ14623 (Uniprot-TrEMBL)
CHOL-N-palmitoyl-L-cysteine-DHH(23-198) ProteinO43323 (Uniprot-TrEMBL)
CHOL-N-palmitoyl-L-cysteine-IHH(28-202) ProteinQ14623 (Uniprot-TrEMBL)
CHOL-N-palmitoyl-L-cysteine-SHH(24-197) ProteinQ15465 (Uniprot-TrEMBL)
CHOL-SHH(24-197) ProteinQ15465 (Uniprot-TrEMBL)
CHOLMetaboliteCHEBI:16113 (ChEBI)
CoA-SHMetaboliteCHEBI:15346 (ChEBI)
DERL2 ProteinQ9GZP9 (Uniprot-TrEMBL)
DHH(33-?) ProteinO43323 (Uniprot-TrEMBL)
DISP2 ProteinA7MBM2 (Uniprot-TrEMBL)
DISP2ProteinA7MBM2 (Uniprot-TrEMBL)
ERLEC1 ProteinQ96DZ1 (Uniprot-TrEMBL)
GPI-GPC5 ProteinP78333 (Uniprot-TrEMBL)
GPI-GPC5ProteinP78333 (Uniprot-TrEMBL)
GPI-cleaved GPC5 ProteinP78333 (Uniprot-TrEMBL)
H2OMetaboliteCHEBI:15377 (ChEBI)
HHATProteinQ5VTY9 (Uniprot-TrEMBL)
Hh precursorsComplexR-HSA-5358318 (Reactome)
Hh-Np:DISP2ComplexR-HSA-5362421 (Reactome)
Hh-Np:GPC5ComplexR-HSA-5362546 (Reactome)
Hh-Np:GPI-GPC5ComplexR-HSA-5362428 (Reactome)
Hh-Np:SCUBE2ComplexR-HSA-5362543 (Reactome)
Hh-NpComplexR-HSA-5358329 (Reactome)
Hh-NpComplexR-HSA-5362423 (Reactome)
Hh-NppComplexR-HSA-5362783 (Reactome)
IHH ProteinQ14623 (Uniprot-TrEMBL)
N-terminal CHOL-Hh fragmentsComplexR-HSA-5358332 (Reactome)
N4glycoAsn-2xHC-DHH(23-396) ProteinO43323 (Uniprot-TrEMBL)
N4glycoAsn-2xHC-IHH(28-411) ProteinQ14623 (Uniprot-TrEMBL)
N4glycoAsn-2xHC-SHH(24-462) ProteinQ15465 (Uniprot-TrEMBL)
N4glycoAsn-DHH(199-396) ProteinO43323 (Uniprot-TrEMBL)
N4glycoAsn-IHH(203-411) ProteinQ14623 (Uniprot-TrEMBL)
N4glycoAsn-SHH(198-462) ProteinQ15465 (Uniprot-TrEMBL)
NOTUMProteinQ6P988 (Uniprot-TrEMBL)
NglycoAsn-Hh precursors:P4HBComplexR-HSA-5490380 (Reactome)
NglycoAsn-Hh precursorsComplexR-HSA-5362382 (Reactome)
OS9 ProteinQ13438 (Uniprot-TrEMBL)
OS9/ERLEC1ComplexR-HSA-5362377 (Reactome)
P4HB ProteinP07237 (Uniprot-TrEMBL)
P4HBProteinP07237 (Uniprot-TrEMBL)
PSMA1 ProteinP25786 (Uniprot-TrEMBL)
PSMA2 ProteinP25787 (Uniprot-TrEMBL)
PSMA3 ProteinP25788 (Uniprot-TrEMBL)
PSMA4 ProteinP25789 (Uniprot-TrEMBL)
PSMA5 ProteinP28066 (Uniprot-TrEMBL)
PSMA6 ProteinP60900 (Uniprot-TrEMBL)
PSMA7 ProteinO14818 (Uniprot-TrEMBL)
PSMA8 ProteinQ8TAA3 (Uniprot-TrEMBL)
PSMB1 ProteinP20618 (Uniprot-TrEMBL)
PSMB10 ProteinP40306 (Uniprot-TrEMBL)
PSMB11 ProteinA5LHX3 (Uniprot-TrEMBL)
PSMB2 ProteinP49721 (Uniprot-TrEMBL)
PSMB3 ProteinP49720 (Uniprot-TrEMBL)
PSMB4 ProteinP28070 (Uniprot-TrEMBL)
PSMB5 ProteinP28074 (Uniprot-TrEMBL)
PSMB6 ProteinP28072 (Uniprot-TrEMBL)
PSMB7 ProteinQ99436 (Uniprot-TrEMBL)
PSMB8 ProteinP28062 (Uniprot-TrEMBL)
PSMB9 ProteinP28065 (Uniprot-TrEMBL)
PSMC1 ProteinP62191 (Uniprot-TrEMBL)
PSMC2 ProteinP35998 (Uniprot-TrEMBL)
PSMC3 ProteinP17980 (Uniprot-TrEMBL)
PSMC4 ProteinP43686 (Uniprot-TrEMBL)
PSMC5 ProteinP62195 (Uniprot-TrEMBL)
PSMC6 ProteinP62333 (Uniprot-TrEMBL)
PSMD1 ProteinQ99460 (Uniprot-TrEMBL)
PSMD10 ProteinO75832 (Uniprot-TrEMBL)
PSMD11 ProteinO00231 (Uniprot-TrEMBL)
PSMD12 ProteinO00232 (Uniprot-TrEMBL)
PSMD13 ProteinQ9UNM6 (Uniprot-TrEMBL)
PSMD14 ProteinO00487 (Uniprot-TrEMBL)
PSMD2 ProteinQ13200 (Uniprot-TrEMBL)
PSMD3 ProteinO43242 (Uniprot-TrEMBL)
PSMD4 ProteinP55036 (Uniprot-TrEMBL)
PSMD5 ProteinQ16401 (Uniprot-TrEMBL)
PSMD6 ProteinQ15008 (Uniprot-TrEMBL)
PSMD7 ProteinP51665 (Uniprot-TrEMBL)
PSMD8 ProteinP48556 (Uniprot-TrEMBL)
PSMD9 ProteinO00233 (Uniprot-TrEMBL)
PSME1 ProteinQ06323 (Uniprot-TrEMBL)
PSME2 ProteinQ9UL46 (Uniprot-TrEMBL)
PSME3 ProteinP61289 (Uniprot-TrEMBL)
PSME4 ProteinQ14997 (Uniprot-TrEMBL)
PSMF1 ProteinQ92530 (Uniprot-TrEMBL)
Palmitoyl-CoAMetaboliteCHEBI:15525 (ChEBI)
RPS27A(1-76) ProteinP62979 (Uniprot-TrEMBL)
SCUBE2 ProteinQ9NQ36 (Uniprot-TrEMBL)
SCUBE2ProteinQ9NQ36 (Uniprot-TrEMBL)
SEL1:SYVN1

dimer:DERL2:VCP

hexamer
ComplexR-HSA-5362378 (Reactome)
SEL1L ProteinQ9UBV2 (Uniprot-TrEMBL)
SHFM1 ProteinP60896 (Uniprot-TrEMBL)
SHH

processing

variants:ERLEC:OS9:SEL1:SYVN1 dimer:DERL2:VCP hexamer
ComplexR-HSA-5387378 (Reactome)
SHH processing variants:OS9/ERLEC1ComplexR-HSA-5362380 (Reactome)
SHH variantsComplexR-HSA-5358456 (Reactome)
SHH(24-462) C198S ProteinQ15465 (Uniprot-TrEMBL)
SHH(24-462) W117G ProteinQ15465 (Uniprot-TrEMBL)
SHH(24-462) W117R ProteinQ15465 (Uniprot-TrEMBL)
SHH(34-?) ProteinQ15465 (Uniprot-TrEMBL)
SRR SHH variants R-HSA-5358452 (Reactome)
SYVN1(1-617) ProteinQ86TM6 (Uniprot-TrEMBL)
UBA52(1-76) ProteinP62987 (Uniprot-TrEMBL)
UBB(1-76) ProteinP0CG47 (Uniprot-TrEMBL)
UBB(153-228) ProteinP0CG47 (Uniprot-TrEMBL)
UBB(77-152) ProteinP0CG47 (Uniprot-TrEMBL)
UBC(1-76) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(153-228) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(229-304) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(305-380) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(381-456) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(457-532) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(533-608) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(609-684) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(77-152) ProteinP0CG48 (Uniprot-TrEMBL)
UbComplexR-HSA-113595 (Reactome)
VCP ProteinP55072 (Uniprot-TrEMBL)
cholesterol site variants of SHH R-HSA-5358450 (Reactome)
phosphateMetaboliteCHEBI:18367 (ChEBI)
ub C-terminal Hh fragmentsComplexR-HSA-5362391 (Reactome)
ub SHH(24-462) C198S ProteinQ15465 (Uniprot-TrEMBL)
ub SHH(24-462) W117G ProteinQ15465 (Uniprot-TrEMBL)
ub SHH(24-462) W117R ProteinQ15465 (Uniprot-TrEMBL)
ub SRR SHH mutants R-HSA-5387374 (Reactome)
ub SRR SHH variants R-HSA-5387370 (Reactome)
ub cholesterol site mutants of SHH R-HSA-5387372 (Reactome)
ub cholesterol site variants of SHH R-HSA-5387368 (Reactome)
ub-C-terminal

Hh

fragments:ERLEC/OS9:SEL1:SYVN1dimer:DERL2:VCP hexamer
ComplexR-HSA-5362408 (Reactome)
ub-N4glycoAsn-DHH(199-396) ProteinO43323 (Uniprot-TrEMBL)
ub-N4glycoAsn-IHH(203-411) ProteinQ14623 (Uniprot-TrEMBL)
ub-N4glycoAsn-SHH(198-462) ProteinQ15465 (Uniprot-TrEMBL)
ub-SHH

processing

variants:ERLEC:OS9:SEL1:SYVN1 dimer:DERL2:VCP hexamer
ComplexR-HSA-5483239 (Reactome)
ub-SHH variantsComplexR-HSA-5387369 (Reactome)
ub-SHH(24-462) C198S ProteinQ15465 (Uniprot-TrEMBL)
ub-SHH(24-462) W117G ProteinQ15465 (Uniprot-TrEMBL)
ub-SHH(24-462) W117R ProteinQ15465 (Uniprot-TrEMBL)

Annotated Interactions

View all...
SourceTargetTypeDatabase referenceComment
26S proteasomemim-catalysisR-HSA-5362448 (Reactome)
26S proteasomemim-catalysisR-HSA-5387392 (Reactome)
ADAM17mim-catalysisR-HSA-5362793 (Reactome)
ADPArrowR-HSA-5362459 (Reactome)
ADPArrowR-HSA-5387389 (Reactome)
ATPR-HSA-5362459 (Reactome)
ATPR-HSA-5387389 (Reactome)
C-terminal

Hh

fragments:ERLEC/OS9:SEL1:SYVN1dimer:DERL2:VCP hexamer
ArrowR-HSA-5362441 (Reactome)
C-terminal

Hh

fragments:ERLEC/OS9:SEL1:SYVN1dimer:DERL2:VCP hexamer
R-HSA-5362412 (Reactome)
C-terminal

Hh

fragments:ERLEC/OS9:SEL1:SYVN1dimer:DERL2:VCP hexamer
mim-catalysisR-HSA-5362412 (Reactome)
C-terminal

Hh

fragments:OS9/ERLEC1
ArrowR-HSA-5362437 (Reactome)
C-terminal

Hh

fragments:OS9/ERLEC1
R-HSA-5362441 (Reactome)
C-terminal Hh fragmentsArrowR-HSA-5358340 (Reactome)
C-terminal Hh fragmentsR-HSA-5362437 (Reactome)
CHOLR-HSA-5358340 (Reactome)
CoA-SHArrowR-HSA-5358343 (Reactome)
DISP2ArrowR-HSA-5362551 (Reactome)
DISP2R-HSA-5362422 (Reactome)
GPI-GPC5R-HSA-5362427 (Reactome)
H2OR-HSA-5362459 (Reactome)
H2OR-HSA-5387389 (Reactome)
HHATmim-catalysisR-HSA-5358343 (Reactome)
Hh precursorsR-HSA-5362386 (Reactome)
Hh-Np:DISP2ArrowR-HSA-5362422 (Reactome)
Hh-Np:DISP2R-HSA-5362551 (Reactome)
Hh-Np:GPC5ArrowR-HSA-5362553 (Reactome)
Hh-Np:GPI-GPC5ArrowR-HSA-5362427 (Reactome)
Hh-Np:GPI-GPC5R-HSA-5362553 (Reactome)
Hh-Np:SCUBE2ArrowR-HSA-5362551 (Reactome)
Hh-NpArrowR-HSA-5358343 (Reactome)
Hh-NpArrowR-HSA-5362549 (Reactome)
Hh-NpR-HSA-5362422 (Reactome)
Hh-NpR-HSA-5362427 (Reactome)
Hh-NpR-HSA-5362549 (Reactome)
Hh-NpR-HSA-5362793 (Reactome)
Hh-NppArrowR-HSA-5362793 (Reactome)
N-terminal CHOL-Hh fragmentsArrowR-HSA-5358340 (Reactome)
N-terminal CHOL-Hh fragmentsR-HSA-5358343 (Reactome)
NOTUMmim-catalysisR-HSA-5362553 (Reactome)
NglycoAsn-Hh precursors:P4HBArrowR-HSA-5358336 (Reactome)
NglycoAsn-Hh precursors:P4HBR-HSA-5358340 (Reactome)
NglycoAsn-Hh precursors:P4HBmim-catalysisR-HSA-5358340 (Reactome)
NglycoAsn-Hh precursorsArrowR-HSA-5362386 (Reactome)
NglycoAsn-Hh precursorsR-HSA-5358336 (Reactome)
OS9/ERLEC1ArrowR-HSA-5362459 (Reactome)
OS9/ERLEC1ArrowR-HSA-5387389 (Reactome)
OS9/ERLEC1R-HSA-5362437 (Reactome)
OS9/ERLEC1R-HSA-5362450 (Reactome)
P4HBArrowR-HSA-5358340 (Reactome)
P4HBR-HSA-5358336 (Reactome)
Palmitoyl-CoAR-HSA-5358343 (Reactome)
R-HSA-5358336 (Reactome) Hh ligands undergo a autoproteolytic cleavage mediated by a conserved residue in the C-terminal region to yield an N-terminal fragment destined for further modification and secretion, and a C-terminal fragment that is subsequently degraded by ERAD (reviewed in Gallet, 2011). Recent work has shown that autoproteolytic cleavage of Hh ligands depends on prior formation of an intramolecular disulphide bond between the catalytic cysteine residue and another conserved cysteine residue in the C-terminal region of the precursor (Chen et al, 2011). Mutation of either of these cysteine residues abolishes cleavage, suggesting that the intramolecular disulphide bond is required to establish a catalytically active conformation of the precursor (Chen et al, 2011).

Prior to the autoproteolytic cleavage reaction, the protein disulphide isomerase P4HB is required to reduce the intramolecular disulphide, freeing the catalytic cysteine side chain for nucleophilic attack. Mutational analysis and co-immunoprecipitation studies support a model where the N-terminal CXXC motif of P4HB forms a mixed disulphide with the non-catalytic cysteine residue of the Hh precursor (Chen et al, 2011.
R-HSA-5358340 (Reactome) Autoproteolytic processing of the Hh precursor is essential for the production of active secreted Hh ligand and mutants that disrupt this processing have been identified in the congenital nervous system disorder holoprosencephaly (Traiffort et al, 2004; Maity et al, 2005; Roessler et al, 2009; reviewed in Jiang et al, 2008). Cleavage of Hh occurs through two nucleophilic substitutions. The first step is mediated by the catalytic cysteine residue, which is found in a conserved G-C-F motif. The cysteine side chain attacks the carbonyl carbon of the main peptide chain between the glycine and cysteine residues, replacing the amino group in the peptide backbone with a thioester linkage (Lee et al, 1994; Porter et al, 1995; Porter et al, 1996a, b; Chen et al, 2011). The second step involves nucleophilic attack of the same carbonyl group by cholesterol. This step displaces the C-terminal fragment (Hh-C) of the Hh precursor and results in the formation of the N-terminal fragment (Hh-Np) modified at its C-terminus by an ester linkage with cholesterol (Porter et al, 1996a, b; Chen et al, 2011). Cholesterol modification appears to contribute to further processing and trafficking of the Hh ligand, as engineered forms of vertebrate and fly Hh that lack cholesterol are not efficiently palmitoylated (Pepinsky et al, 1998). Cholesterol also restricts the diffusion of the secreted ligand by interacting with the lipid bilayer of the secreting cell. Consistent with this, aberrant activation of Hh target genes is seen in the absence of cholesterol modification (Peters et al, 2004; Guerrero et al, 2007; Li et al, 2006; Huang et al, 2007).

R-HSA-5358343 (Reactome) In addition to being modified by cholesterol at its C-terminal end, the N-terminal fragment of Hh (Hh-Np) is also palmitoylated by the O-acyltransferase HHAT (Pepinsky et al, 1998; Charmoun et al 2001; Chen et al, 2004; Hardy and Resh, 2007). HHAT-mediated palmitoylation of Hh can be recapitulated in vitro and in vivo, and the cholesterol- and palmitoyl-modified N-terminal fragment represents the predominant secreted form of Hh in vivo (Buglino and Resh, 2008; Buglino and Resh, 2010; Taipale et al, 2000). Mutation or depletion of the HHAT enzyme and mutation of the palmitoyl acceptor cysteine in Hh itself abrogates palmitoylation of the ligand and reduces Hh signaling (Chen et al, 2004; Chamoun et al, 2001; Pepinsky et al, 1998; Callier et al, 2014).
R-HSA-5362386 (Reactome) Proteomic studies show that the C-termini of SHH and IHH are N-glycosylated (Liu et al, 2005). A N278A mutant of SHH does not undergo cholesterol-mediated autoproteolysis suggesting that glycosylation is a prerequisite for this processing step (Huang et al, 2013).
R-HSA-5362412 (Reactome) SYVN1 ubiquitinates Hh-C as part of the retrotranslocon that targets these Hh fragments for degradation through the ERAD pathway. Both depletion of SYVN1 by siRNA and expression of a catalytically inactive form of the enzyme strongly inhibits Hh-C degradation. Consistent with this, a dominant negative version of SYVN1 abrogates the polyubiquitination of Hh-C as assessed by IP-Western from HEK293 cells (Chen et al, 2011).
R-HSA-5362422 (Reactome) Long range signaling of Hh depends on a number of additional factors that promote the release and spread of Hh-Np ligand. Dispatched2 (DISP2) is a 12-pass transmembrane protein that was identified as being required for release and long-range signaling by Hh-Np (Burke et al, 1999; Ma et al, 2002; Nakano et al, 2004). In mammals, DISP2 has been shown to bind directly to the cholesterol moiety of Hh-Np through its first extracellular region, and this interaction is required for secretion and long-range signaling. Mutants of DISP2 that are inactive in promoting Hh long-range signaling show tighter binding to Hh-Np, suggesting that these mutants interfere with the release of Hh ligand from the plasma membrane (Tukachinsky et al, 2012). Although this pathway shows DISP2 and Hh-Np interacting at the plasma membrane, it is possible that the interaction occurs earlier in the secretory pathway and that DISP2 escorts Hh-Np to the cell surface.

In addition to binding to DISP2, the cholesterol moiety of Hh-Np is also bound by the secreted protein SCUBE2 (Tukachinsky et al, 2012; Creanga et al, 2012). Like DISP2, SCUBE2 is required for long-range signaling by Hh-Np (Johnson et al, 2012; Tukachinsky et al, 2012; Creanga et al, 2012). DISP2 and SCUBE2 recognize distinct portions of the cholesterol group on Hh-Np, suggesting a possible hand-off mechanism at the plasma membrane that allows the release of Hh from the secreting cell (Tukachinsky et al, 2012; Creanga et al, 2012).

R-HSA-5362427 (Reactome) The establishment of a signaling gradient of Hh-Np is modulated in part by the interaction of the ligand with heparin sulphate proteoglycans (HSPGs) in the extracellular matrix (ECM) of the secreting cell. Interactions with HSPGs can influence Hh oligomerization and also impact the lateral and long-range spread of Hh ligand (reviewed in Gallet, 2011; Briscoe and Therond, 2013). Interactions with HSPGs can stimulate or restrict Hh signaling depending on the context and the particular proteoglycans involved (see for instance Witt et al, 2013; Li et al, 2011; Capurro et al, 2005; Capurro et al, 2012; reviewed in Gallet, 2011).

In vertebrate cells, the GPI-anchored HSPG glypican 5 (GPC5) has been shown to stimulate Hh signaling by promoting the interaction between SHH ligand and the PTCH1 receptor (Li et al, 2011; Witt et al, 2013). SHH and PTCH1 binding depends on the GAG chains of GPC5, as versions lacking the GAG insertion sites are compromised for both ligand and receptor binding, and these proteins do not stimulate Hh signaling (Li et al, 2011). Amplification of GPC5 has been observed in 20% of rhabdomyosarcomas (Williamson et al, 2007), and aberrant activation of Hh signaling in these cells promotes cellular proliferation (Li et al, 2011).
R-HSA-5362437 (Reactome) Promotion of the cholesterol-mediated autocleavage reaction is the only well documented role for the C-terminal region of intact Hh (reviewed in Briscoe and Therond, 2013), and recent in vitro studies suggest that the Hh-C fragment generated by autocleavage is subsequently targeted to the endoplasmic reticulum-associated degradation (ERAD) pathway (Chen et al, 2011; Huang et al, 2013). This pathway delivers N-glycosylated ER-resident substrates to a retrotranslocation channel, where they are ubiquitinated and translocated to the cytosol for proteasome-mediated degradation in an ATP-ase dependent fashion (reviewed in Vembar and Brodsky, 2008). Recognition and targettng of ER proteins for the ERAD pathway depends at least in part on modification and binding of the glycosyl groups. Consistent with this, depletion of the lectins OS9 and ERLEC1 abrogates degradation of the Hh-C fragments (Chen et al, 2011). OS9 and ERLEC1 may target Hh-C to the retrotranslocation channel by virtue of their interaction with SEL1, an ER membrane protein with established roles in the ERAD pathway (Christianson et al, 2008; Mueller et al, 2008; Hosokawa et al, 2008; Hosokawa et al, 2009).
R-HSA-5362441 (Reactome) After binding to OS9/ERLEC1, the Hh C-terminal fragments are recruited to the ER membrane through a lectin-SEL1 interaction. SEL1 is a component of a multiprotein retrotranslocation complex in the ER membrane that also includes the E3 ubiquitin ligase SYVN1 (also known as HRD1; present as a dimer), DERL2 and the hexameric ATPase VCP (Christianson et al, 2008; Hosokawa et al, 2008; Mueller et al, 2008; Chen et al, 2011; Huang et al, 2013; reviewed in Vembar and Brodsky, 2008). Depletion of SEL1, SYVN1, VCP or DERL2 results in the accumulation of the Hh-C in the ER lumen (Chen et al, 2011; Huang et al, 2013).
R-HSA-5362448 (Reactome) After retrotranslocation to the cytosol, Hh-C is degraded by the proteasome (Chen et al, 2011; Huang et al, 2013).
R-HSA-5362450 (Reactome) Like the WT C-terminal fragment of Hh, processing-defective variant precursors of full-length Hh are also targetted for degradation by the endoplasmic reticulum-associated degradtion (ERAD) pathway (Chen et al, 2011; Huang et al, 2013). This pathway delivers N-glycosylated ER-resident substrates to a retrotranslocation channel, where they are ubiquitinated and translocated to the cytosol for proteasome-mediated degradation in an ATP-ase dependent fashion (reviewed in Vembar and Brodsky, 2008). Recognition and targetting of ER proteins for the ERAD pathway depends at least in part by modification and binding of the glycosyl groups, and as is the case for the WT C-terminal fragment, lectins OS9 and ERLEC1 are required for the degradation of processing-defective variants of Hh (Chen et al, 2011). OS9 and ERLEC1 may target substrates to the retrotranslocation channel by virtue of their interaction SEL1, an ER membrane protein with established roles in the ERAD pathway (Christianson et al, 2008; Mueller et al, 2008; Hosokawa et al, 2008; Hosokawa et al, 2009).
R-HSA-5362459 (Reactome) The ATPase activity of VCP is required for the retrotranslocation of Hh-C across the ER membrane (Chen et al, 2011). Although in this pathway, the VCP hexamer is shown as part of the SEL1:SYVN1:DERL2 retrotranslocon, the details, order of events and even the full complement of protein players in this process are not known. In yeast, the VCP homologue Cdc48 is associated with two additional proteins Ufd1 and Npl4 -both of which are also conserved in mammals- and this complex interacts with several ER components including derlins and the yeast SYVN1 homologue, Hrd1 (reviewed in Vembar and Brodsky, 2009). Consistent with the yeast data, VCP interacts with DERL2 by co-immunoprecipitation in HEK293 cells (Huang et al, 2013).
R-HSA-5362549 (Reactome) Hh-Np traffics to the plasma membrane where it may cluster in lipid rafts. Cholesterol modification is thought to contribute to this transit and targeting, possibly by promoting interaction with the lipid raft components caveolin and flotillin2, although this has not been demonstrated in mammalian cells (reviewed in Gallet, 2011). Cholesterol and lipid modification also impact the effective signaling range of the secreted ligand: due to the hydrophobic nature of these modifications, Hh-Np remains closely associated with the plasma membrane of the secreting cell, where it is competent for short-range signaling to adjacent cells. Long-range signaling depends on a number of possible mechanisms to extract the ligand from the secreting cell, including oligomerization of ligand into micelle-like structures, cleavage of the C-terminal cholesterol moiety by metalloproteases, or interaction with additional factors that help promote release from the plasma membrane (reviewed in Gallet, 2011; Briscoe and Therond, 2013).
R-HSA-5362551 (Reactome) SCUBE2 is a member of a family of secreted proteins that is required for long-range signaling Hh signaling (Johnson et al, 2012; Tukachinsky et al, 2012; Creanga et al, 2013). Like DISP2, SCUBE2 binds to the cholesterol moiety of the Hh ligand, although the structural elements recognized by the two proteins are distinct. This suggests a model where Hh is released from the plasma membrane to the extracellular region via a DISP2 to SCUBE hand-off (Tukachinsky et al, 2012; Creanga et al, 2013).
R-HSA-5362553 (Reactome) Notum is a secreted protein with phospholipase C activity that has been implicated in promoting long range Hh signaling in Drosophila (Ayers et al, 2010; Eugster et al, 2007; Takeo et al, 2005; Han et al, 2005; Giraldez et al, 2002). Notum is thought to cleave the GPI-anchor from Dally, a Drosophila glypican, to release Hh-Dally complexes from the plasma membrane of the Hh-secreting cell (Ayers et al, 2010; Han et al, 2005), although this cleavage has not been directly demonstrated. In cultured mammalian cells, NOTUM has been shown to cleave the GPI anchor of a number of glypicans to promote their release from the plasma membrane (Traister et al, 2008).
R-HSA-5362793 (Reactome) Hh-Np can be untethered from the plasma membrane of the secreting cell by ADAM17-mediated cleavage of the lipidated N- and C-termini (Dierker et al, 2009; Ohlig et al, 2011; Ohlig et al, 2012). Shedding of SHH Np from the plasma membrane is abrogated by siRNA depletion of ADAM17, as well as in the presence of metalloprotease inhibitors or mutation of the ADAM17 catalytic E406 residue (Dierker et al, 2009). ADAM17-mediated cleavage is stimulated by heparin sulphate and likely occurs in the context of a HSPG-SHH complex although specific HSPGs have not been identified (Dierker et al, 2009). Cleavage of the cholesterol- and palmitoyl-modified termini is suggested to promote a SHH conformation that is competent to bind to the Patched receptor (Ohlig et al, 2011).
R-HSA-5387386 (Reactome) As is the case for the WT Hh C-terminal fragment, siRNA depletion of SEL1 and SYVN1 inhibits the degradation of processing-defective Hh mutants, suggesting these versions of Hh are also targets for ERAD-mediated degradation (Chen et al, 2011; Huang et al, 2013).
R-HSA-5387389 (Reactome) Depletion of the ATPase VCP results in the stabilization of processing-defective Hh variants in the ER lumen, supporting the notion that, as is the case for the WT Hh C-terminal fragment, these peptides are also substrates for ERAD (Chen et al, 2011; Huang et al, 2013).
R-HSA-5387392 (Reactome) After retrotranslocation to the cytosol, processing-defective Hh variants are degraded by the proteasome (Chen et al, 2011; Huang et al, 2013).
R-HSA-5483238 (Reactome) Processing-defective SHH variants are ubiquitinated by SYVN1 (Chen et al, 2011).
SCUBE2R-HSA-5362551 (Reactome)
SEL1:SYVN1

dimer:DERL2:VCP

hexamer
ArrowR-HSA-5362459 (Reactome)
SEL1:SYVN1

dimer:DERL2:VCP

hexamer
ArrowR-HSA-5387389 (Reactome)
SEL1:SYVN1

dimer:DERL2:VCP

hexamer
R-HSA-5362441 (Reactome)
SEL1:SYVN1

dimer:DERL2:VCP

hexamer
R-HSA-5387386 (Reactome)
SHH

processing

variants:ERLEC:OS9:SEL1:SYVN1 dimer:DERL2:VCP hexamer
ArrowR-HSA-5387386 (Reactome)
SHH

processing

variants:ERLEC:OS9:SEL1:SYVN1 dimer:DERL2:VCP hexamer
R-HSA-5483238 (Reactome)
SHH

processing

variants:ERLEC:OS9:SEL1:SYVN1 dimer:DERL2:VCP hexamer
mim-catalysisR-HSA-5483238 (Reactome)
SHH processing variants:OS9/ERLEC1ArrowR-HSA-5362450 (Reactome)
SHH processing variants:OS9/ERLEC1R-HSA-5387386 (Reactome)
SHH variantsR-HSA-5362450 (Reactome)
UbArrowR-HSA-5362448 (Reactome)
UbArrowR-HSA-5387392 (Reactome)
UbR-HSA-5362412 (Reactome)
UbR-HSA-5483238 (Reactome)
phosphateArrowR-HSA-5362459 (Reactome)
phosphateArrowR-HSA-5387389 (Reactome)
ub C-terminal Hh fragmentsArrowR-HSA-5362459 (Reactome)
ub C-terminal Hh fragmentsR-HSA-5362448 (Reactome)
ub-C-terminal

Hh

fragments:ERLEC/OS9:SEL1:SYVN1dimer:DERL2:VCP hexamer
ArrowR-HSA-5362412 (Reactome)
ub-C-terminal

Hh

fragments:ERLEC/OS9:SEL1:SYVN1dimer:DERL2:VCP hexamer
R-HSA-5362459 (Reactome)
ub-C-terminal

Hh

fragments:ERLEC/OS9:SEL1:SYVN1dimer:DERL2:VCP hexamer
mim-catalysisR-HSA-5362459 (Reactome)
ub-SHH

processing

variants:ERLEC:OS9:SEL1:SYVN1 dimer:DERL2:VCP hexamer
ArrowR-HSA-5483238 (Reactome)
ub-SHH

processing

variants:ERLEC:OS9:SEL1:SYVN1 dimer:DERL2:VCP hexamer
R-HSA-5387389 (Reactome)
ub-SHH

processing

variants:ERLEC:OS9:SEL1:SYVN1 dimer:DERL2:VCP hexamer
mim-catalysisR-HSA-5387389 (Reactome)
ub-SHH variantsArrowR-HSA-5387389 (Reactome)
ub-SHH variantsR-HSA-5387392 (Reactome)
Personal tools